Skip to main content
Erschienen in: Molecular Diagnosis & Therapy 6/2014

01.12.2014 | Original Research Article

Polymorphisms of CYP2C9, VKORC1, MDR1, APOE and UGT1A1 Genes and the Therapeutic Warfarin Dose in Brazilian Patients with Thrombosis: A Prospective Cohort Study

verfasst von: Vanessa Cristina de Oliveira Almeida, Daniel Dias Ribeiro, Karina Braga Gomes, Ana Lúcia Brunialti Godard

Erschienen in: Molecular Diagnosis & Therapy | Ausgabe 6/2014

Einloggen, um Zugang zu erhalten

Abstract

Background

There are several pharmacogenetic algorithms to determine the warfarin doses required in patients treated for thromboembolism, but they only explain 60 % of dose variation, suggesting that other genes may influence the dose required.

Objectives

This study aimed to evaluate the impact of clinical factors and CYP2C9*2, CYP2C9*3, VKORC1-1639G>A, MDR1 3435C>T, APOE* ε4, and UGT1A1(TA)n polymorphisms on the warfarin dose required, especially in those individuals requiring a high warfarin dose.

Methods

We studied 116 Brazilian patients who received warfarin therapy for thromboembolism. Associations between dose variability and age, body mass index (BMI), gender, use of warfarin antagonists, and genetic polymorphisms were examined.

Results

CYP2C9*2, CYP2C9*3, VKORC1-1639G>A, and APOE *ε4 were associated with lower warfarin doses. Of these subjects, 21 % required a warfarin dose higher than 70 mg/week, which was associated with a BMI greater than 25 kg/m2, use of warfarin antagonists, and the presence of the MDR1 3435T allele and UGT1A1(TA) 7 polymorphism. These individuals were considered to exhibit warfarin resistance. The individuals with the MDR1 3435TT genotype required a dose 21 % higher than that required by 3435CT and 3435CC individuals. The UGT1A1(TA) 7 allele was positively correlated with the warfarin dose.

Conclusion

CYP2C9*2, CYP2C9*3, VKORC1-1639G>A, and APOE *ε4 were associated with lower warfarin doses, while MDR1 3435C>T and UGT1A1(TA) n polymorphisms were associated with a requirement for higher doses. This is the first study to evaluate warfarin resistance, APOE *ε4 and UGT1A1(TA) n genotypes in the Brazilian population, and the association of these two genotypes with warfarin dose required.
Literatur
2.
Zurück zum Zitat The International Warfarin Pharmacogenetics Consortium. Estimation of the warfarin dose with clinical and pharmacogenetic Data. N Engl J Med. 2009;360:753–64.PubMedCentralCrossRef The International Warfarin Pharmacogenetics Consortium. Estimation of the warfarin dose with clinical and pharmacogenetic Data. N Engl J Med. 2009;360:753–64.PubMedCentralCrossRef
3.
Zurück zum Zitat Johnson JA, Gong L, Whirl-Carrillo M, Gage BF, Scott SA, et al. Clinical Pharmacogenetics implementation consortium guidelines for CYP2C9 and VKORC1 genotypes and warfarin dosing. Clin Pharmacol Ther. 2011;90:625–9.PubMedCentralPubMedCrossRef Johnson JA, Gong L, Whirl-Carrillo M, Gage BF, Scott SA, et al. Clinical Pharmacogenetics implementation consortium guidelines for CYP2C9 and VKORC1 genotypes and warfarin dosing. Clin Pharmacol Ther. 2011;90:625–9.PubMedCentralPubMedCrossRef
4.
Zurück zum Zitat Kangelaris KN, Stephen B, Nussbaum RL, Garcia DA, Tice JA. Genetic testing before anticoagulation? A systematic review of pharmacogenetic dosing of warfarin. J Gen Intern Med. 2009;24:1171.CrossRef Kangelaris KN, Stephen B, Nussbaum RL, Garcia DA, Tice JA. Genetic testing before anticoagulation? A systematic review of pharmacogenetic dosing of warfarin. J Gen Intern Med. 2009;24:1171.CrossRef
5.
Zurück zum Zitat Wadelius M, Chen LY, Eriksson N, Bumpstead S, Ghori J, et al. Association of warfarin dose with genes involved in its action and metabolism. Hum Genet. 2007;121:23–34.PubMedCentralPubMedCrossRef Wadelius M, Chen LY, Eriksson N, Bumpstead S, Ghori J, et al. Association of warfarin dose with genes involved in its action and metabolism. Hum Genet. 2007;121:23–34.PubMedCentralPubMedCrossRef
6.
Zurück zum Zitat Wadelius M, Chen LY, Lindh JC, Eriksson N, Ghori MJ, et al. The largest prospective warfarin-treated cohort supports genetic forecasting. Blood. 2009;113:784–92.PubMedCentralPubMedCrossRef Wadelius M, Chen LY, Lindh JC, Eriksson N, Ghori MJ, et al. The largest prospective warfarin-treated cohort supports genetic forecasting. Blood. 2009;113:784–92.PubMedCentralPubMedCrossRef
7.
Zurück zum Zitat D’Andrea G, D’Ambrosio RL, Perna PD, Chetta M, Santacroce R, et al. A polymorphism in the VKORC1 gene is associated with an interindividual variability in the dose-anticoagulant effect of warfarin. Blood. 2005;105:645–9.PubMedCrossRef D’Andrea G, D’Ambrosio RL, Perna PD, Chetta M, Santacroce R, et al. A polymorphism in the VKORC1 gene is associated with an interindividual variability in the dose-anticoagulant effect of warfarin. Blood. 2005;105:645–9.PubMedCrossRef
8.
Zurück zum Zitat Botton MR, Bandinelli E, Rohde LE, Amon LC, Hutz MH. Influence of genetic, biological and pharmacological factors on warfarin dose in a Southern Brazilian population of European ancestry. Br J Clin Pharmacol. 2011;72:442–50.PubMedCentralPubMedCrossRef Botton MR, Bandinelli E, Rohde LE, Amon LC, Hutz MH. Influence of genetic, biological and pharmacological factors on warfarin dose in a Southern Brazilian population of European ancestry. Br J Clin Pharmacol. 2011;72:442–50.PubMedCentralPubMedCrossRef
9.
Zurück zum Zitat Kohnke H, Scordo MG, Pengo V, Padrini R, Wadelius M. Apolipoprotein E (APOE) and warfarin dosing in an Italian population. Eur J Clin Pharmacol. 2005;61:781–3.PubMedCrossRef Kohnke H, Scordo MG, Pengo V, Padrini R, Wadelius M. Apolipoprotein E (APOE) and warfarin dosing in an Italian population. Eur J Clin Pharmacol. 2005;61:781–3.PubMedCrossRef
10.
Zurück zum Zitat Cavallari LH, Butler C, Langaee TY, Wardak N, Patel SR, et al. Association of apolipoprotein e genotype with duration of time to achieve a stable warfarin dose in african-american patients. Pharmacotherapy. 2011;31:785–92.PubMedCrossRef Cavallari LH, Butler C, Langaee TY, Wardak N, Patel SR, et al. Association of apolipoprotein e genotype with duration of time to achieve a stable warfarin dose in african-american patients. Pharmacotherapy. 2011;31:785–92.PubMedCrossRef
11.
Zurück zum Zitat Kimmel SE, Christie J, Kealey C, Chen Z, Price M, et al. Apolipoprotein E genotype and warfarin dosing among Caucasians and African Americans. Pharmacogenomics J. 2008;8:53–60.PubMedCrossRef Kimmel SE, Christie J, Kealey C, Chen Z, Price M, et al. Apolipoprotein E genotype and warfarin dosing among Caucasians and African Americans. Pharmacogenomics J. 2008;8:53–60.PubMedCrossRef
12.
Zurück zum Zitat Almeida VCO, Ferreira ACS, Ribeiro DD, Gomes KBB, Fernandes APSM, et al. Association of the C3435T polymorphism of the MDR1 gene and therapeutic doses of warfarin in thrombophilic patients. J Thromb Haemost. 2011;9:2120–2.CrossRef Almeida VCO, Ferreira ACS, Ribeiro DD, Gomes KBB, Fernandes APSM, et al. Association of the C3435T polymorphism of the MDR1 gene and therapeutic doses of warfarin in thrombophilic patients. J Thromb Haemost. 2011;9:2120–2.CrossRef
13.
Zurück zum Zitat Bratton SM, Mosher CM, Khallouki F, Finel M, Court MH, et al. Analysis of R- and S-hydroxywarfarin glucuronidation catalyzed by human liver microsomes and recombinant UDP-glucuronosyltransferases. J Pharmacol Exp Ther. 2012;340:46–55.PubMedCentralPubMedCrossRef Bratton SM, Mosher CM, Khallouki F, Finel M, Court MH, et al. Analysis of R- and S-hydroxywarfarin glucuronidation catalyzed by human liver microsomes and recombinant UDP-glucuronosyltransferases. J Pharmacol Exp Ther. 2012;340:46–55.PubMedCentralPubMedCrossRef
14.
Zurück zum Zitat Sinxadi M, Blockman M. Warfarin resistance. Cardiovasc J Afr. 2008;19:215–7.PubMed Sinxadi M, Blockman M. Warfarin resistance. Cardiovasc J Afr. 2008;19:215–7.PubMed
15.
Zurück zum Zitat Loebstein R, Dvoskin I, Halkin H, Vecsler M, Lubetsky A, et al. A coding VKORC1 Asp36Tyr polymorphism predisposes to warfarin resistance. Blood. 2007;109:2477–80.PubMedCrossRef Loebstein R, Dvoskin I, Halkin H, Vecsler M, Lubetsky A, et al. A coding VKORC1 Asp36Tyr polymorphism predisposes to warfarin resistance. Blood. 2007;109:2477–80.PubMedCrossRef
16.
Zurück zum Zitat Harrington DJ, Gorska R, Wheeler R, Davidson S, Murden S, et al. Pharmacodynamic resistance to warfarin is associated with nucleotide substitutions in VKORC1. J Thromb Haemost. 2008;6:1663–70.PubMedCrossRef Harrington DJ, Gorska R, Wheeler R, Davidson S, Murden S, et al. Pharmacodynamic resistance to warfarin is associated with nucleotide substitutions in VKORC1. J Thromb Haemost. 2008;6:1663–70.PubMedCrossRef
18.
Zurück zum Zitat Sakaeda T, Nakamura T, Horinouchi M, Kakumoto M, Ohmoto N, et al. MDR1 genotype-related pharmacokinetics of digoxin after single oral administration in healthy Japanese subjects. Pharm Res. 2001;18:1400–4.PubMedCrossRef Sakaeda T, Nakamura T, Horinouchi M, Kakumoto M, Ohmoto N, et al. MDR1 genotype-related pharmacokinetics of digoxin after single oral administration in healthy Japanese subjects. Pharm Res. 2001;18:1400–4.PubMedCrossRef
19.
Zurück zum Zitat Beutler E, Gelbart T, Demina A. Racial variability in the UDP-glucuronosultransferase 1 (UGT1A1) promoter: a balanced polymorphism for regulation of bilirubin metabolism. Proc Natl Acad Sci. 1998;95:8170–4.PubMedCentralPubMedCrossRef Beutler E, Gelbart T, Demina A. Racial variability in the UDP-glucuronosultransferase 1 (UGT1A1) promoter: a balanced polymorphism for regulation of bilirubin metabolism. Proc Natl Acad Sci. 1998;95:8170–4.PubMedCentralPubMedCrossRef
20.
Zurück zum Zitat White RH. The epidemiology of venous thromboembolism. Circulation. 2003;107:1–8.CrossRef White RH. The epidemiology of venous thromboembolism. Circulation. 2003;107:1–8.CrossRef
22.
Zurück zum Zitat Jensen BP, Chin PK, Roberts RL, Begg EJ. Influence of adult age on the total and free clearance and protein binding of (R)- and (S)-warfarin. Br J Clin Pharmacol. 2012;74:797–805.PubMedCentralPubMedCrossRef Jensen BP, Chin PK, Roberts RL, Begg EJ. Influence of adult age on the total and free clearance and protein binding of (R)- and (S)-warfarin. Br J Clin Pharmacol. 2012;74:797–805.PubMedCentralPubMedCrossRef
23.
Zurück zum Zitat Perini JA, Struchiner CJ, Silva-Assunção E, Santana IS, Rangel F, et al. Pharmacogenetics of warfarin: development of a dosing algorithm for brazilian patients. Clin Pharmacol Ther. 2008;84:722–8.PubMedCrossRef Perini JA, Struchiner CJ, Silva-Assunção E, Santana IS, Rangel F, et al. Pharmacogenetics of warfarin: development of a dosing algorithm for brazilian patients. Clin Pharmacol Ther. 2008;84:722–8.PubMedCrossRef
24.
Zurück zum Zitat Watzka M, Geisen C, Bevans CG, Sittinger K, Spohn G, et al. Thirteen novel VKORC1 mutations associated with oral anticoagulant resistance: insights into improved patient diagnosis and treatment. J Thromb Haemost. 2011;9:109–18.PubMedCrossRef Watzka M, Geisen C, Bevans CG, Sittinger K, Spohn G, et al. Thirteen novel VKORC1 mutations associated with oral anticoagulant resistance: insights into improved patient diagnosis and treatment. J Thromb Haemost. 2011;9:109–18.PubMedCrossRef
25.
Zurück zum Zitat Vianna JR, Perini JA, Rondinelli E, Suarez-Kurtz G. CYP2C9 genotypes and the pharmacokinetics of tenoxicam in Brazilians. Clin Pharmacol Ther. 2004;76:18–26.CrossRef Vianna JR, Perini JA, Rondinelli E, Suarez-Kurtz G. CYP2C9 genotypes and the pharmacokinetics of tenoxicam in Brazilians. Clin Pharmacol Ther. 2004;76:18–26.CrossRef
26.
Zurück zum Zitat Limdi NA, Wadelius M, Cavallari L, Eriksson N, Crawford DC, International Warfarin Pharmacogenetics Consortium, et al. Warfarin pharmacogenetics: a single VKORC1 polymorphism is predictive of dose across 3 racial groups. Blood. 2010;115:3827–34.PubMedCentralPubMedCrossRef Limdi NA, Wadelius M, Cavallari L, Eriksson N, Crawford DC, International Warfarin Pharmacogenetics Consortium, et al. Warfarin pharmacogenetics: a single VKORC1 polymorphism is predictive of dose across 3 racial groups. Blood. 2010;115:3827–34.PubMedCentralPubMedCrossRef
28.
Zurück zum Zitat Sconce EA, Daly AK, Khan TI, Wynne HA, Kamali F. APOE genotype makes a small contribution to warfarin dose requirements. Pharmacogenet Genomics. 2006;16:609–11.PubMedCrossRef Sconce EA, Daly AK, Khan TI, Wynne HA, Kamali F. APOE genotype makes a small contribution to warfarin dose requirements. Pharmacogenet Genomics. 2006;16:609–11.PubMedCrossRef
29.
Zurück zum Zitat Kohnke H, Sorlin K, Granath G, Wadelius M. Warfarin dose related to apolipoprotein E (APOE) genotype. Eur J Clin Pharmacol. 2005;61:381–8.PubMedCrossRef Kohnke H, Sorlin K, Granath G, Wadelius M. Warfarin dose related to apolipoprotein E (APOE) genotype. Eur J Clin Pharmacol. 2005;61:381–8.PubMedCrossRef
30.
31.
Zurück zum Zitat Kim Y, Smith A, Wu AH. C3435T polymorphism of MDR1 gene with warfarin resistance. Clin Chim Acta. 2013;425:34–6.PubMedCrossRef Kim Y, Smith A, Wu AH. C3435T polymorphism of MDR1 gene with warfarin resistance. Clin Chim Acta. 2013;425:34–6.PubMedCrossRef
32.
Zurück zum Zitat Issac MS, El-Nahid MS, Wissa MY. Is there a role for MDR1, EPHX1 and protein Z gene variants in modulation of warfarin dosage? A study on a cohort of the Egyptian population. Mol Diagn Ther. 2014;18(1):73–83.PubMedCrossRef Issac MS, El-Nahid MS, Wissa MY. Is there a role for MDR1, EPHX1 and protein Z gene variants in modulation of warfarin dosage? A study on a cohort of the Egyptian population. Mol Diagn Ther. 2014;18(1):73–83.PubMedCrossRef
33.
Zurück zum Zitat Marques SC, Ikediobi ON. The clinical application of UGT1A1 pharmacogenetic testing: Gene–environment interactions. Hum Genomics. 2010;4:238–49.PubMedCentralPubMed Marques SC, Ikediobi ON. The clinical application of UGT1A1 pharmacogenetic testing: Gene–environment interactions. Hum Genomics. 2010;4:238–49.PubMedCentralPubMed
34.
Zurück zum Zitat Fertrin KY, Gonçalves MS, Saad ST, Costa FF. Frequencies of UDP- glucuronosyltransferase 1 (UGT1A1) gene promoter polymorphisms among distinct ethnic groups from Brazil. Am J Med Genet. 2002;108:117–9.PubMedCrossRef Fertrin KY, Gonçalves MS, Saad ST, Costa FF. Frequencies of UDP- glucuronosyltransferase 1 (UGT1A1) gene promoter polymorphisms among distinct ethnic groups from Brazil. Am J Med Genet. 2002;108:117–9.PubMedCrossRef
35.
Zurück zum Zitat Stojiljkovic M, Patrinos GP, Pavlovic S. Clinical applicability of sequence variations in genes related to drug metabolism. Curr Drug Metab. 2011;12(5):445–54.PubMedCrossRef Stojiljkovic M, Patrinos GP, Pavlovic S. Clinical applicability of sequence variations in genes related to drug metabolism. Curr Drug Metab. 2011;12(5):445–54.PubMedCrossRef
36.
Zurück zum Zitat Santos PCJL, Soares RAG, Santos DBG, Nascimento RM, Coelho GL. CYP2C19 and ABCB1 gene polymorphisms are differently distributed according to ethnicity in the Brazilian general population. BMC Med Genet. 2011;12:13.PubMedCentralPubMedCrossRef Santos PCJL, Soares RAG, Santos DBG, Nascimento RM, Coelho GL. CYP2C19 and ABCB1 gene polymorphisms are differently distributed according to ethnicity in the Brazilian general population. BMC Med Genet. 2011;12:13.PubMedCentralPubMedCrossRef
Metadaten
Titel
Polymorphisms of CYP2C9, VKORC1, MDR1, APOE and UGT1A1 Genes and the Therapeutic Warfarin Dose in Brazilian Patients with Thrombosis: A Prospective Cohort Study
verfasst von
Vanessa Cristina de Oliveira Almeida
Daniel Dias Ribeiro
Karina Braga Gomes
Ana Lúcia Brunialti Godard
Publikationsdatum
01.12.2014
Verlag
Springer International Publishing
Erschienen in
Molecular Diagnosis & Therapy / Ausgabe 6/2014
Print ISSN: 1177-1062
Elektronische ISSN: 1179-2000
DOI
https://doi.org/10.1007/s40291-014-0121-4

Weitere Artikel der Ausgabe 6/2014

Molecular Diagnosis & Therapy 6/2014 Zur Ausgabe

Acknowledgement to Referees

Acknowledgement to Referees

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

„Jeder Fall von plötzlichem Tod muss obduziert werden!“

17.05.2024 Plötzlicher Herztod Nachrichten

Ein signifikanter Anteil der Fälle von plötzlichem Herztod ist genetisch bedingt. Um ihre Verwandten vor diesem Schicksal zu bewahren, sollten jüngere Personen, die plötzlich unerwartet versterben, ausnahmslos einer Autopsie unterzogen werden.

Hirnblutung unter DOAK und VKA ähnlich bedrohlich

17.05.2024 Direkte orale Antikoagulanzien Nachrichten

Kommt es zu einer nichttraumatischen Hirnblutung, spielt es keine große Rolle, ob die Betroffenen zuvor direkt wirksame orale Antikoagulanzien oder Marcumar bekommen haben: Die Prognose ist ähnlich schlecht.

Schlechtere Vorhofflimmern-Prognose bei kleinem linken Ventrikel

17.05.2024 Vorhofflimmern Nachrichten

Nicht nur ein vergrößerter, sondern auch ein kleiner linker Ventrikel ist bei Vorhofflimmern mit einer erhöhten Komplikationsrate assoziiert. Der Zusammenhang besteht nach Daten aus China unabhängig von anderen Risikofaktoren.

Semaglutid bei Herzinsuffizienz: Wie erklärt sich die Wirksamkeit?

17.05.2024 Herzinsuffizienz Nachrichten

Bei adipösen Patienten mit Herzinsuffizienz des HFpEF-Phänotyps ist Semaglutid von symptomatischem Nutzen. Resultiert dieser Benefit allein aus der Gewichtsreduktion oder auch aus spezifischen Effekten auf die Herzinsuffizienz-Pathogenese? Eine neue Analyse gibt Aufschluss.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.